Genetic Architecture of Circulating Very-Long-Chain (C24:0 and C22:0) Ceramide Concentrations

Sharon Cresci¹, Ruibo Zhang², Qiong Yang², Meredith S. Duncan³,⁴,⁵, Vanessa Xanthakis²,³,⁴, Xuntian Jiang¹, Ramachandran S Vasan²,⁵,⁶, Jean E. Schaffer¹, Linda R. Peterson¹

¹Diabetic Cardiovascular Disease Center, Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA
²Department of Biostatistics and Epidemiology, Boston University School of Public Health, Boston, MA, USA
³Division of Cardiovascular Medicine and Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA
⁴Framingham Heart Study, Framingham, MA, USA
⁵Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University, Boston, MA, USA
⁶Section of Cardiology, Department of Medicine, Boston University, Boston, MA, USA

Abstract

Objective—Total ceramide concentrations are linked with increased insulin resistance and cardiac dysfunction. However, recent studies have demonstrated that plasma concentrations of specific very-long-chain fatty ceramides (C24:0 and C22:0) are associated with a reduced incidence of coronary heart disease and all-cause mortality. We hypothesized that specific genetic loci are associated with plasma C22:0 and C24:0 concentrations.

Methods—Heritability and genome-wide association studies of plasma C24:0 and C22:0 ceramide concentrations were performed among 2,217 participants in the Framingham Heart Study.
Study Offspring Cohort, adjusting for cardiovascular risk factor covariates and cardiovascular drug treatment.

**Results**—The multivariable-adjusted heritability for C22:0 and C24:0 ceramides was 0.42 (standard error [SE], 0.07; \(p=1.8\times 10^{-9}\)) and 0.25 (SE, 0.08; \(p=0.00025\)), respectively. Nineteen single nucleotide polymorphisms (SNPs), all on chromosome 20, significantly associated with C22:0 concentrations; the closest gene to these variants was *SPTLC3*. The lead SNP (rs4814175) significantly associated with 3% lower plasma C22:0 concentrations (\(p=2.83\times 10^{-11}\)). Nine SNPs, all on chromosome 20 and close to *SPTLC3*, were significantly associated with C24:0 ceramide concentrations. All 9 were also significantly related to plasma C22:0 levels. The lead SNP (rs168622) was significantly associated with 10% lower plasma C24:0 ceramide concentrations (\(p=9.94\times 10^{-9}\)).

**Conclusion**—SNPs near the *SPTLC3* gene, which encodes serine palmitoyltransferase long chain base subunit 3 (*SPTLC3*; part of the enzyme that catalyzes the rate-limiting step of de novo sphingolipid synthesis) were associated with plasma C22:0 and C24:0 ceramide concentrations. These results are biologically plausible and suggest that *SPTLC3* may be a potential therapeutic target for C24:0 and C22:0 ceramide modulation.

**Keywords**
Genomics; Lipidomics; Cardiovascular disease; Genome-Wide Association Study

**INTRODUCTION**

Cardiovascular disease (CVD) is the top cause of death worldwide. Several risk factors for CVD have been identified, including cholesterol levels, hypertension, and others. However, even when combined, these known risk factors do not completely predict incident CVD. Clearly, the identification of novel biomarkers associated with CVD would yield an improved understanding of disease etiology, aid in the prediction of incident disease, and point toward new therapeutic targets.

In addition to cholesterol and triglycerides, ceramides are another type of bioactive lipid species that are of interest as potential markers of CVD risk. The identification of novel biomarkers associated with these diseases would improve our understanding of the etiology of CVD, assist in the prediction of incident CVD, and shed light on novel potential therapeutic targets. Broad inhibition of ceramide synthesis prevents diet- and glucocorticoid-induced insulin resistance in mice, thus implicating ceramides in the promotion of metabolic and CVD.\(^1\)\(^2\) Moreover, in several murine models of metabolic cardiomyopathy, and in humans, total cardiac ceramide accumulation is associated with cardiac dysfunction.\(^3\)\(^-\)\(^5\) Recently, however, studies by our group\(^6\) have demonstrated that plasma levels of specific very-long-chain molecular species of ceramides (C24:0 and C22:0) are associated with a decreased risk of coronary heart disease (CHD), heart failure (HF), and/or all-cause mortality. For example, the relative risks of CHD, HF, and all-cause mortality for each 3-unit increase in plasma C24:0 ceramide levels were 0.79, 0.75, and 0.78, respectively, even after adjusting for standard CVD risk factors including blood cholesterol. Other groups have
demonstrated that a lower risk of CVD events was associated with increased plasma C24:0 ceramide and/or C22:0 ceramide concentrations in patients with known CHD.\textsuperscript{7,8}

There is both a \textit{de novo} and a salvage pathway for sphingolipid and ceramide production, and specific ceramide synthases create ceramides of specific chain lengths. Both ceramide synthase 2 and 3 can generate the very-long-chain C22:0 and C24:0 species.\textsuperscript{9}

However, the genomic links between these species are incompletely understood. We hypothesized that specific loci would be associated with these 2 important complex lipid species. To test this hypothesis, we leveraged existing genome-wide scans to examine variants associated with C22:0 and C24:0 ceramide concentrations. Our primary aim was to identify variants that met genome-wide significance. However, with an exploratory, hypothesis-generating aim, we lowered our threshold for significance (to $p<1E^{-5}$) and used pathway analyses to identify which genes had the strongest potential causal association and would be suitable for further analyses.

**MATERIALS AND METHODS**

1. **Study population**

   We evaluated clinical, genetic, and metabolomic data from the participants in the Framingham Heart Study (FHS) Offspring Cohort who took part in the eighth examination cycle. The FHS samples, inclusion criteria, events, and adjudication have previously been described.\textsuperscript{10} We have recently published a paper describing the association of the plasma C24:0/C16:0 ceramide ratio with clinical outcomes using the same samples.\textsuperscript{6} Participants were excluded if they did not have plasma samples available for ceramide concentration analysis or if their information on covariates (e.g., diabetes status) was missing. Participants were also excluded if they did not consent to making their genetic data available for analysis. A total of 804 subjects who took part in examination after 8 were excluded.

2. **Lipidomic analyses**

   The lipidomic analyses used for these samples have previously been described.\textsuperscript{6,11} Briefly, we used a robust, reproducible, and fully validated liquid chromatography/tandem mass spectrometry assay to quantify C24:0 and C22:0 ceramide levels in frozen plasma samples from the FHS Offspring Cohort.\textsuperscript{11} Five percent of the samples were run in duplicate for quality control. A full description of the lipidomics assay has been presented by Jiang et al.\textsuperscript{11}

3. **Genotyping and imputation**

   Genotyping was conducted using the Affymetrix (Santa Clara, CA, USA) 500K and Affymetrix 50K Supplemental Array. Samples were excluded if they had a call rate <97%, extreme heterozygosity, or a high Mendelian error rate. Imputation to the 1000 Genomes (August 2010) reference panel was performed on the data (after appropriate quality control measures) using MACH version 1.0.16 for SNPs that passed the following criteria: call rate ≥97%, probability of deviation from Hardy-Weinberg equilibrium ≥E-6, mishap $p ≥E-9$, ≥100 Mendelian errors, and minor allele frequency (MAF) ≥1%. After discarding
imputed SNPs with an information content < 0.3, the total number of (genotyped + imputed) SNPs available for analysis was 9,346,801.

4. Statistical analysis

Polygenic heritability — The heritability of continuous C22:0 and C24:0 ceramide concentrations was estimated using variance component models implemented in SOLAR. The heritability estimation (i.e., the estimation of the ratio of genetic variance to phenotypic variance) was adjusted for age, sex, diabetes, smoking status, systolic blood pressure, anti-hypertensive treatment, body mass index (BMI), and 2 associated principal components (PC1, PC9) of population stratification.

Genome-wide association analysis — Linear mixed-effects models were fitted to relate each genetic variant, assuming an additive genetic effect model, to continuous C22:0 and C24:0 ceramide concentrations, accounting for the exact family structure with a kinship coefficient matrix using the lmekin function in the R coxme package. The analyses were adjusted for the same covariates listed above in the polygenic heritability section. A p-value of less than 5E-8 was considered to indicate genome-wide significance.

Pathway analyses — For our secondary, hypothesis-generating aim, DEPICT (v1, https://data.broadinstitute.org/mpg/depict) was used to prioritize the genes identified from a genome-wide association study (GWAS) at p<1E-5 with the strongest potential causal association, to identify enriched pathway(s), and to determine tissues and cell types in which genes from associated loci were highly expressed.

RESULTS

1. Study sample

The baseline characteristics of our study sample are shown in Table 1. The mean age of the FHS participants in this study was 65.6 (±8.7) years and 45% were men. There was a low prevalence of smoking and diabetes (9% and 12%, respectively), indicating that this was a generally healthy cohort. Nearly half of the subjects were on antihypertensive medications, although their blood pressure was well controlled.

2. Heritability

The multivariable-adjusted heritability for C22:0 and C24:0 ceramide levels was 0.42 (standard error [SE], 0.07; p=1.8E-9) and 0.25 (SE, 0.08; p=0.00025), respectively, after adjustment for age, sex, diabetes, smoking status, systolic blood pressure, anti-hypertension treatment, BMI, and 2 associated principal components (PC1, PC9) of population stratification.

3. Genome-wide association analysis

In total, 9,346,801 common variants (MAF>0.05), genotyped or imputed, from 1000 Genomes imputation were tested for associations with plasma C22:0 and C24:0 ceramide levels in 2,217 FHS subjects after adjustment for confounders. All SNPs (MAF>0.05,
imputation quality > 0.3) with association $p$-values reaching genome-wide significance ($< 5\times 10^{-8}$) are shown in Table 2 (C22:0 ceramide) and Table 3 (C24:0 ceramide).

The associations of 19 SNPs with plasma C22:0 ceramide concentrations reached genome-wide significance (Table 2 and Fig. 1). All 19 SNPs were on a similar region of chromosome 20 and were in strong linkage disequilibrium with each other (Fig. 2). The closest gene to these variants was SPTLC3, the gene encoding serine palmitoyltransferase long chain base subunit 3 (SPTLC3). The lead SNP (rs4814175) was significantly associated with 3% lower plasma C22:0 ceramide concentrations ($p = 2.83\times 10^{-11}$).

Nine SNPs were significantly associated with plasma C24:0 ceramide concentrations (Table 3 and Fig. 3). All 9 were on chromosome 20, close to SPTLC3, and in strong linkage disequilibrium with each other (Fig. 4). The lead SNP (rs168622) was significantly associated with 10% lower plasma C24:0 ceramide concentrations ($p = 9.94\times 10^{-9}$).

Since for both phenotypes, the variants that reached genome-wide significance were located in a similar region of chromosome 20 and were in strong linkage disequilibrium with each other, conditional analysis was performed on the lead SNPs to assess the independent contribution of each SNP. When the analysis was conditioned on the lead SNPs (rs4814175 for C22:0 ceramide and rs168622 for C24:0 ceramide, respectively), the effects of the other genome-wide significant variants were attenuated, indicating that the 19 SNPs (C22:0 ceramide) and 9 SNPs (C24:0 ceramide) captured the same genetic effect.

Although no other SNPs reached genome-wide significance in the conditional analysis, a few borderline significant signals emerged: rs191288953 ($p = 7.41\times 10^{-8}$; chromosome 7; closest gene SDK1) and rs79935880 ($p = 7.69\times 10^{-8}$; chromosome 10; near MTRNR2L7) for C22:0 ceramide levels and rs34432959 ($p = 8.68\times 10^{-8}$) and rs12963655 ($p = 8.00\times 10^{-8}$) for C24:0 ceramide levels, both of which are located near SYT4 on chromosome 18. The conditional analysis results of independent SNPs ($r^2 < 0.1$, MAF > 0.05, imputation quality > 0.3) with $p$-values $\leq 1\times 10^{-5}$ for the associations are presented in Supplementary Table 1 for C22:0 ceramide (n=76) and in Supplementary Table 2 for C24:0 ceramide (n=65) concentrations. To further assess these variants for biological plausibility, we performed pathway analyses. For plasma C22:0 ceramide levels, the DEPICT gene prioritization results showed a false discovery rate of $< 0.20$ for rs79935880 and the enrichment results suggested a false positive rate of $< 0.20$ for ENSG00000138107 and REACTOME_SIGNALING_BY_ROBO_RECEPTOR. No significant results (false discovery rate $< 0.20$) were identified for plasma C24:0 ceramide levels.

**DISCUSSION**

Ceramides are complex lipids composed of sphingosine and a fatty acid of varying acyl chain length. Ceramides have pleiotropic effects. They are found in cell membranes and can affect cell signaling, apoptosis, differentiation, senescence, and proliferation, as well as hormonal and stress responses. Studies of ceramides have shown that high total ceramide concentrations in plasma and/or tissue are related to increased insulin resistance, CVD, and cardiovascular death in patients with HF.$^{5,13-15}$ However, higher concentrations of some
very-long-chain ceramides in the plasma predict a decreased risk of CHD, HF, and/or all-cause mortality.\textsuperscript{6,8} We hypothesized that plasma C22:0 and C24:0 ceramide concentrations would be heritable and would be associated with genetic variants.

In this study, we demonstrated the heritability of plasma concentrations of C22:0 and C24:0 ceramides. We also showed that 19 SNPs on chromosome 20 were associated with plasma C22:0 ceramide concentrations and that 9 SNPs on chromosome 20 were associated with plasma C24:0 ceramide concentrations at a GWAS level of significance ($p \leq 5 \times 10^{-8}$). The SNPs were in strong linkage disequilibrium with each other, and when a conditional analysis on the lead SNP was performed (conditioned on rs4814175 for C22:0 ceramide and rs168622 for C24:0 ceramide), the effects of the other genome-wide significant variants were attenuated to non-significance, indicating that the SNPs captured the same genetic effect. All of the SNPs were within 60 kb of the gene encoding SPTLC3.

SPTLC3 is a subunit of the enzyme serine palmitoyl transferase (SPT), which catalyzes the rate-limiting step of de novo synthesis of the sphingoid backbone of sphingolipids, which are precursors for ceramide synthesis. SPT condenses a fatty acyl-coenzyme A and serine to create a sphingoid base.\textsuperscript{16} SPT is composed of 1 or more heterodimers, including the SPTLC1 subunit, which links the SPT enzyme to the membrane, and a catalytic subunit (e.g., SPTLC3 or SPTLC2).\textsuperscript{16} SPTLC3 is highly expressed in the myocardium.\textsuperscript{16} The SPTLC3 subunit enables the SPT enzyme to generate either d16 or d18 sphingoid bases, which are precursors in ceramide production.\textsuperscript{16} The specific sphingoid base of the ceramides measured in this study was 18:1. Different sphingoid base lengths can cause different effects. For example, d16 bases enhance cell death pathways.\textsuperscript{16} In addition, different acyl chain lengths appear to have differential effects on disease pathways. Prior investigators have linked certain ceramide species (C18:1, C18:0, C20:0, and C24:1 dihydroceramide), with conditions related to CVD, including diabetes, insulin resistance, and increased plasma levels of inflammatory mediators, such as tumor necrosis factor alpha.\textsuperscript{17,18} One small study has also linked C22:0 levels with insulin resistance.\textsuperscript{17}

Genetic polymorphisms in SPTLC3 associated with metabolic phenotypes have also been previously reported. A recent GWAS investigating 163 metabolic traits revealed that 9 SNPs, including the SPTLC rs168622 variant, were associated with the variability of serum levels of different metabolites and serum metabolite ratios (thought to be representative of enzymatic reaction rates).\textsuperscript{19} Specifically, it was found that the SPTLC rs168622 G variant was associated with higher C24:1 concentrations and lower C24:0/C24:1 concentrations.\textsuperscript{19} Furthermore, as mentioned above, higher C24:1 levels have been associated with insulin resistance. It is challenging to explain exactly how changing 1 subunit (SPTLC3) in a multi-complex enzyme (SPT) would result in these and other changes in the concentrations of ceramides of different fatty acyl chain lengths. Changes in SPTLC3 may alter SPT activity or cause compensatory changes in the expression of other subunits or activity that may lead to different chain length preferences. In addition, multiple biochemical pathways (e.g., the salvage pathway in addition to the de novo pathway) lead to ceramide synthesis. Precisely how changing the efficiency of a single pathway will alter the balance of acyl chains is complex and not readily predictable, as different pathways may lead to preferences for different acyl chain incorporation, and there could be changes in the expression or activity of...
other inputs to ceramide synthesis. Other investigators have shown that carriers of the SPTLC3 rs168622 GG variant had lower relative mRNA expression of SPTLC3 and lower total hepatic lipid content. Since the SPTLC3 rs168622 GG variant leads to lower mRNA expression of SPTLC3, it is likely that those individuals have less SPTLC3-mediated generation of d16 (and d18) bases, leading to lower levels of ceramides composed of d16 bases, which are linked with cell death. Taken together, these prior observations regarding sphingoid base and/or fatty acyl chain effects of SPTLC3 SNPs lend biological plausibility to our findings and suggest potential molecular mechanisms connecting our genomic findings with CVD and its risk factors.

As part of our hypothesis-generating aim, we identified 2 SNPs and 1 pathway that did not reach genome-wide significance, but had a false discovery rate of less than 20%: rs79935880 (p=8.05E-7), ENSG00000138107 (p=2.42E-6) and REACTOME_SIGNALING_BY_ROBO_RECEPTOR (p=2.28E-5). The rs79935880 SNP is a variant of the ANKRD30A gene, which encodes a transcription factor that is only expressed in breast and testicular tissue. ENSG00000138107 is located near ACTR1A, which encodes actin related protein 1A, a subunit of dynactin. REACTOME_SIGNALING_BY_ROBO_RECEPTOR is a set of 30 genes that are involved in signaling by the Robo receptor; these genes encode transmembrane receptors that regulate axonal guidance and cell migration and are important in development. While the biological plausibility of rs79935880 and REACTOME_SIGNALING_BY_ROBO_RECEPTOR may not be immediately apparent, ENSG00000138107 has obvious potential biological relevance. Ceramides are signaling molecules that are upregulated in response to several physiological stressors. The specific effects of these complex lipids appear to relate to the type of tissue they are in, as well as their acyl chain length. Ceramides have a variety of effects, including pro-apoptosis, pro-mitophagy, pro-survival, and pro-autophagy. Specific ceramide species have been demonstrated to promote programmed cell death through a cascade of events involving ceramide-mediated channels and a loss of mitochondrial outer membrane integrity that facilitate the release of cytochrome c and other pro-apoptotic proteins into the cytoplasm, ultimately resulting in mitophagy and mitochondria-induced apoptosis. In contrast, C24:0 ceramide interferes with this process and has predominantly anti-apoptotic effects. Given that dynactin is involved in transport between the endoplasmic reticulum and Golgi apparatus, as well as the formation and movement of lysosomes and endosomes, this gene may be an important component of the pathway(s) that are influenced by C22:0 and C24:0 ceramides, a finding that may provide further insight into the mechanisms underlying the effects of ceramides.

Our results validate and extend the findings of previous investigators. Hicks and colleagues assessed whether a GWAS analysis could identify variants associated with the concentrations of 33 circulating sphingolipids (24 sphingomyelins and 9 ceramides) in 5 large, presumed to be healthy, European populations. The 20p12.1 locus was found to have the strongest association with serum ceramide concentrations. Although no SNP reached genome-wide significance in any of the 5 populations, rs680379 reached genome-wide significance for its associations with both C22:0 and C24:0 ceramide concentrations in a meta-analysis of all 5 populations. In contrast, when Lemaitre and colleagues investigated whether a GWAS analysis could identify variants associated with the total plasma
phospholipid and erythrocyte levels of 3 saturated, very-long-chain fatty acids (20:0, 22:0, and 24:0, which included ceramides with these fatty acid acyl chains—C20:0, C22:0, and C24:0—as well as other lipid moieties) in a meta-analysis of 7 cohorts comprising 10,129 individuals of European ancestry, no genome-wide significant associations were found with circulating levels of 22:0 or 24:0 fatty acids. However, C20:0 ceramide concentrations were associated with 7 variants in strong linkage disequilibrium with each other on chromosome 20p12.1; the most significant variant was rs680379.27 Our findings support those of Hicks and colleagues.26 We also observed that the rs680379 variant reached genome-wide significance for its associations with both C22:0 and C24:0 ceramide concentrations. Our findings in the FHS Offspring Cohort provide important validation and confirmation that this locus is an important genetic determinant of C22:0 and C24:0 ceramide concentrations.

The identification of SNPs that are associated with plasma ceramide concentrations is important for several reasons. Patients’ SPTLC3 genotype status should be considered, and potentially adjusted for, when assessing plasma ceramide concentrations and determining individual risk and prognosis. We speculate that in the future, use of genotype-guided, precision medicine approaches might identify specific patient groups that could benefit from unique, targeted therapeutic interventions.

Our study should be interpreted in the context of several potential limitations. First, the FHS Offspring Cohort contains white individuals of European ancestry. Thus, it is unclear whether these results are generalizable to individuals of different racial or ethnic groups. Second, our conditional analyses that identified rs79935880, ENSG00000138107, and REACTOME_SIGNALING_BY_ROBO_RECEPTOR as potentially significant should be considered as exploratory, as they have not been validated in an independent cohort. However, these findings, and particularly the association with ACTR1A, are intriguing as they have biological plausibility and may lead to insights into novel pathways and therapeutics that could benefit specific populations. In addition, associations (between SNPs related to SPTLC3 and very-long-chain ceramides, as well as between very-long-chain ceramides and CVD) do not prove causation. Future studies are needed to further investigate the possible causative roles of genes and specific ceramides for disease. Lastly, the possible effects of the specific SNPs identified as being significantly related to plasma C22:0 and C24:0 ceramides on other ceramide species is beyond the scope of this study.

In summary, we have identified SNPs on chromosome 20 associated with plasma C22:0 and C24:0 ceramide concentrations in individuals from the FHS Offspring Cohort. These SNPs are near SPTLC3, the gene encoding SPTLC3, which catalyzes the rate-limiting step of de novo sphingolipid synthesis. Our results are biologically plausible and suggest that SPTLC3 may be a novel therapeutic target for C24:0 and C22:0 ceramide modulation.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

Funding
REFERENCES

1. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoehn KL, Summers SA. Lipid mediators of insulin resistance. Nutr Rev 2007;65:S39–S46. [PubMed: 17605313]

2. Ussher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010;59:2453–2464. [PubMed: 20522596]

3. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 2001;107:813–822. [PubMed: 11285300]

4. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, et al. Ceramide is a cardiotoxic in lipotoxic cardiomyopathy. J Lipid Res 2008;49:2101–2112. [PubMed: 18515784]

5. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012;125:2844–2853. [PubMed: 22586279]

6. Peterson LR, Xanthakis V, Duncan MS, Gross S, Friedrich N, Völzke H, et al. Ceramide remodeling and risk of cardiovascular events and mortality. J Am Heart Assoc 2018;7:e007931. [PubMed: 29728014]

7. Laaksonen R, Ekroos K, Sysi-Aho M, Hilmo V, Viheravaa T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J 2016;37:1967–1976. [PubMed: 27125947]

8. Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylvänne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab 2014;99:E45–E52. [PubMed: 24243630]

9. Brice SE, Cowart LA. Sphingolipid Metabolism and analysis in metabolic disease In: Cowart LA, editor. Sphingolipids and metabolic diseases. New York (NY): Landes Bioscience/Springer Science +Business Media, LLC; 2011 p.1–17.

10. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med 1975;4:518–525. [PubMed: 1208363]

11. Jiang H, Hsu FF, Farmer MS, Peterson LR, Schaffer JE, Ory DS, et al. Development and validation of LC-MS/MS method for determination of very long acyl chain (C22:0 and C24:0) ceramides in human plasma. Anal Bioanal Chem 2013;405:7357–7365. [PubMed: 23857140]

12. Chen MH, Yang Q. RVFam: an R package for rare variant association analysis with family data. Bioinformatics 2016;32:624–626. [PubMed: 26508760]

13. de Mello VD, Lankinen M, Schwab U, Kolehmainen M, Lehto S, Seppänen-Laakso T, et al. Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009;52:2612–2615. [PubMed: 19669729]

14. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000;97:1784–1789. [PubMed: 10677535]

15. Yu J, Pan W, Shi R, Yang T, Li Y, Yu G, et al. Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can J Cardiol 2015;31:357–363. [PubMed: 25746025]

16. Russo SB, Tidhar R, Futerman AH, Cowart LA. Myristate-derived d16:0 sphingolipids constitute a cardiac sphingolipid pool with distinct synthetic routes and functional properties. J Biol Chem 2013;288:13397–13409. [PubMed: 23530041]
17. Lopez X, Goldfine AB, Holland WL, Gordillo R, Scherer PE. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J Pediatr Endocrinol Metab 2013;26:995–998. [PubMed: 23612696]

18. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, DeFronzo RA, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009;58:337–343. [PubMed: 19008343]

19. Illig T, Gieger C, Zhai G, Römisch-Margl W, Wang-Sattler R, Prehn C, et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010;42:137–141. [PubMed: 20037589]

20. Mirkov S, Myers JL, Ramírez J, Liu W. SNPs affecting serum metabolomic traits may regulate gene transcription and lipid accumulation in the liver. Metabolism 2012;61:1523–1527. [PubMed: 22738862]

21. Ogretmen B Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer 2018;18:33–50. [PubMed: 29147025]

22. Morad SA, Cabot MC. Ceramide-orchestrated signalling in cancer cells. Nat Rev Cancer 2013;13:51–65. [PubMed: 23235911]

23. Sassa T, Suto S, Okayasu Y, Kihara A. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells. Biochim Biophys Acta 2012;1821:1031–1037. [PubMed: 22579584]

24. Park JW, Park WJ, Futerman AH. Ceramide synthases as potential targets for therapeutic intervention in human diseases. Biochim Biophys Acta 2014;1841:671–681. [PubMed: 24021978]

25. Stiban J, Perera M. Very long chain ceramides interfere with C16-ceramide-induced channel formation: a plausible mechanism for regulating the initiation of intrinsic apoptosis. Biochim Biophys Acta 2015;1848:561–567. [PubMed: 25462172]

26. Hicks AA, Pramstaller PP, Johansson A, Vitart V, Rudan I, Ugoctsai P, et al. Genetic determinants of circulating sphingolipid concentrations in European populations. PLoS Genet 2009;5:e1000672. [PubMed: 19798445]

27. Lemaitre RN, King IB, Kabagambe EK, Wu JH, McKnight B, Manichaikul A, et al. Genetic loci associated with circulating levels of very long-chain saturated fatty acids. J Lipid Res 2015;56:176–184. [PubMed: 25378659]

J Lipid Atheroscler. Author manuscript; available in PMC 2020 June 02.
Fig. 1.
Manhattan plot of associations between SNPs and plasma C22:0 ceramide concentrations in 2,217 Framingham Heart Study subjects. SNPs are plotted on the x-axis according to their position on each chromosome, with the $-\log_{10} p$-value on the y-axis. The upper dashed horizontal line indicates the threshold for genome-wide significance, $5 \times 10^{-8}$. SNP, single-nucleotide polymorphism.
Fig. 2.
Regional association and recombination plot for SNPs associated with plasma C22:0 ceramide concentrations. The $-\log_{10} p$-values for associations with C22:0 ceramide concentrations are presented on the left y-axis. The chromosome 20 position in megabases (Mb) is presented on the x-axis. The plotted SNPs are presented in the top panel and the relative positions of genes in the region are presented in the bottom panel. The purple diamond indicates the SNP (rs4814175) with the most significant association with C22:0 ceramide concentrations. The surrounding SNPs are colored according to their pairwise correlation ($r^2$) with rs4814175. Estimated recombination hotspots in HapMap (i.e., recombination rates) are represented by blue lines (quantified on the right y-axis). SNP, single-nucleotide polymorphism.
Fig. 3. Manhattan plot of associations between SNPs and plasma C24:0 ceramide concentrations in 2,217 Framingham Heart Study subjects. SNPs are plotted on the x-axis according to their position on each chromosome, with the $-\log_{10} p$-value on the y-axis. The upper dashed horizontal line indicates the threshold for genome-wide significance, $5\times10^{-8}$. SNP, single-nucleotide polymorphism.
Fig. 4.
Regional association and recombination plot for SNPs associated with plasma C24:0 ceramide concentrations. The $-\log_{10}$ $p$-values for association with C24:0 ceramide concentrations are represented on the left $y$-axis. The chromosome 20 position in megabases (Mb) is presented on the $x$-axis. The plotted SNPs are presented in the top panel and the relative positions of genes in the region are represented in the bottom panel. The purple diamond indicates the SNP (rs168622) with the most significant association with C22:0 ceramide concentrations. Surrounding SNPs are colored according to their pairwise correlation ($r^2$) with rs168622. Estimated recombination hotspots in HapMap (i.e., recombination rates) are represented by blue lines (quantified on the right $y$-axis). SNP, single-nucleotide polymorphism.
Table 1.

Characteristics of study participants

| Variable                        | FHS (n=2,217) | Min   | Max   |
|---------------------------------|---------------|-------|-------|
| Age (yr)                        | 65.62±8.74    |       |       |
| Male sex (%)                    | 995 (45)      |       |       |
| Systolic blood pressure (mmHg) | 128±17        |       |       |
| BMI (kg/m²)                     | 27.98±5.10    |       |       |
| Smokers (%)                     | 209 (9)       |       |       |
| Diabetes mellitus (%)           | 269 (12)      |       |       |
| Hypertension treatment (%)      | 1,013 (46)    |       |       |
| Total to HDL cholesterol ratio  | 3.46±1.06     | 1.40  | 11.26 |
| CER 22:0 (μg/mL)                | 0.60±0.17     | 0.10  | 1.53  |
| CER 24:0 (μg/mL)                | 2.24±0.61     | 0.30  | 5.81  |

Values are mean±standard deviation for continuous variables and number (percentage) for categorical variables.

FHS, Framingham Heart Study; BMI, body mass index; HDL, high-density lipoprotein; CER, ceramide.
Table 2.
Top GWAS results for C22:0 ceramide (p<5E-8, MAF>0.05)

| SNPID       | rsID | Type    | Chr | Phys_location | Number | variMAF | β    | SE   | p-value   | Nearest gene | Distance to nearest gene |
|-------------|------|---------|-----|---------------|--------|---------|------|------|-----------|--------------|--------------------------|
| 20:12959094 | rs4814175 | SNP     | 20  | 12959094      | 2,217  | 0.22    | -0.031 | 0.005 | 2.83E-11  | SPTLC3       | 30533                    |
| 20:12966089 | rs168622 | SNP     | 20  | 12966089      | 2,217  | 0.23    | -0.031 | 0.005 | 3.02E-11  | SPTLC3       | 23538                    |
| 20:12962718 | rs364585 | SNP     | 20  | 12962718      | 2,217  | 0.23    | -0.031 | 0.005 | 3.12E-11  | SPTLC3       | 26909                    |
| 20:12958687 | rs438568 | SNP     | 20  | 12958687      | 2,217  | 0.23    | -0.031 | 0.005 | 3.47E-11  | SPTLC3       | 30940                    |
| 20:12959885 | rs1321940| SNP     | 20  | 12959885      | 2,217  | 0.23    | -0.031 | 0.005 | 3.56E-11  | SPTLC3       | 29742                    |
| 20:12959398 | rs4814176| SNP     | 20  | 12959398      | 2,217  | 0.23    | -0.031 | 0.005 | 3.56E-11  | SPTLC3       | 30229                    |
| 20:12969400 | rs680379 | SNP     | 20  | 12969400      | 2,217  | 0.22    | -0.031 | 0.005 | 3.99E-11  | SPTLC3       | 20227                    |
| 20:12973521 | rs686548 | SNP     | 20  | 12973521      | 2,217  | 0.21    | -0.031 | 0.005 | 6.76E-11  | SPTLC3       | 16106                    |
| 20:12958492:A_ACT | NA | Insertion | 20  | 12958492      | 2,217  | 0.21    | -0.031 | 0.005 | 1.61E-10  | SPTLC3       | 31135                    |
| 20:12942649 | rs3848744| SNP     | 20  | 12942649      | 2,217  | 0.21    | -0.029 | 0.005 | 4.58E-09  | SPTLC3       | 46978                    |
| 20:12944067 | rs3848745| SNP     | 20  | 12944067      | 2,217  | 0.21    | -0.029 | 0.005 | 4.66E-09  | SPTLC3       | 45560                    |
| 20:12945963 | rs3903703| SNP     | 20  | 12945963      | 2,217  | 0.21    | -0.029 | 0.005 | 4.78E-09  | SPTLC3       | 43664                    |
| 20:12947532 | rs4814173| SNP     | 20  | 12947532      | 2,217  | 0.21    | -0.029 | 0.005 | 4.95E-09  | SPTLC3       | 42095                    |
| 20:12940649 | rs6041735| SNP     | 20  | 12940649      | 2,217  | 0.20    | -0.029 | 0.005 | 5.14E-09  | SPTLC3       | 48978                    |
| 20:12950606 | rs3848746| SNP     | 20  | 12950606      | 2,217  | 0.21    | -0.029 | 0.005 | 5.50E-09  | SPTLC3       | 39021                    |
| 20:12952964 | rs2327452| SNP     | 20  | 12952964      | 2,217  | 0.21    | -0.029 | 0.005 | 5.59E-09  | SPTLC3       | 36663                    |
| 20:12953934 | rs2327451| SNP     | 20  | 12953934      | 2,217  | 0.21    | -0.029 | 0.005 | 5.73E-09  | SPTLC3       | 35693                    |
| 20:12943737 | rs3843765| SNP     | 20  | 12943737      | 2,217  | 0.20    | -0.029 | 0.005 | 5.74E-09  | SPTLC3       | 45890                    |
| 20:12955601 | rs4508668| SNP     | 20  | 12955601      | 2,217  | 0.21    | -0.028 | 0.005 | 5.98E-09  | SPTLC3       | 34026                    |

GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; Chr, chromosome; SE, standard error; NA, not available.
Table 3.
Top GWAS results for C24:0 ceramide (p<5E-8, MAF>0.05)

| SNPID       | rsID   | Type    | Chr | Phys_location | Number | variMAF | β     | SE  | p-value | Nearest gene | Distance to nearest gene |
|-------------|--------|---------|-----|---------------|--------|---------|-------|-----|---------|--------------|--------------------------|
| 20:12966089 | rs168622| SNP     | 20  | 12966089      | 2,217  | 0.22985726 | -0.100 | 0.017 | 9.94E-09 | SPTLC3       | 23538                    |
| 20:12962718 | rs364585| SNP     | 20  | 12962718      | 2,217  | 0.22783744 | -0.100 | 0.018 | 1.10E-08 | SPTLC3       | 26909                    |
| 20:12969400 | rs680379| SNP     | 20  | 12969400      | 2,217  | 0.22385646 | -0.101 | 0.018 | 1.12E-08 | SPTLC3       | 20227                    |
| 20:12959094 | rs4814175| SNP    | 20  | 12959094      | 2,217  | 0.22384246 | -0.101 | 0.018 | 1.14E-08 | SPTLC3       | 30533                    |
| 20:12958687 | rs438568| SNP     | 20  | 12958687      | 2,217  | 0.2258695  | -0.100 | 0.018 | 1.32E-08 | SPTLC3       | 30940                    |
| 20:12959885 | rs1321940| SNP   | 20  | 12959885      | 2,217  | 0.22623451 | -0.100 | 0.018 | 1.32E-08 | SPTLC3       | 29742                    |
| 20:12959398 | rs4814176| SNP    | 20  | 12959398      | 2,217  | 0.22557234 | -0.100 | 0.018 | 1.46E-08 | SPTLC3       | 30229                    |
| 20:12973521 | rs686548| SNP     | 20  | 12973521      | 2,217  | 0.21422157 | -0.102 | 0.018 | 1.51E-08 | SPTLC3       | 16106                    |
| 20:12958492:A_ACT | NA  | Insertion | 20  | 12958492    | 2,217  | 0.21169913 | -0.101 | 0.018 | 2.94E-08 | SPTLC3       | 31135                    |

GWAS, genome-wide association study; MAF, minor allele frequency; SNP, single-nucleotide polymorphism; Chr, chromosome; SE, standard error; NA, not available.